Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A tau-protein kinase is an enzyme in the protein-serine/threonine kinase family that catalyzes the phosphorylation of tau protein, primarily at serine/threonine residues. Tau kinases include multiple enzymes such as glycogen synthase kinase-3 beta (GSK3β), cyclin-dependent kinase 5 (CDK5), and tau-tubulin kinases (TTBK1, TTBK2), which participate in both physiological signaling and pathological processes. Dysregulated activity or overexpression leads to tau hyperphosphorylation, resulting in tau aggregation and neurofibrillary tangle formation characteristic of Alzheimer's disease and related tauopathies. Tau-protein kinases are considered an important but challenging therapeutic target for neurodegenerative disease. Multiple kinase inhibitors have been tested for efficacy in reducing tau pathology, with limited clinical success to date due to complex physiological roles and limited specificity.
Inhibition of tau hyperphosphorylation, Inhibition of kinase activity (e.g., GSK3β inhibition), Stabilization of protein phosphatase 2A (PP2A) to increase tau dephosphorylation
18 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tau-protein kinase.